https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-08-19 / Front Immunol 2025;16:1633100
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-08-19 / Front Immunol 2025;16:16331002025-08-19 00:00:002025-08-19 00:00:00Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-03-04 / Cancers (Basel) 2025 Mar;17(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-03-04 / Cancers (Basel) 2025 Mar;17(5)2025-03-04 00:00:002025-03-17 07:36:12The Complexity of Malignant Glioma Treatment
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):92025-01-23 00:00:002025-01-23 00:00:00WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-12-23 / Clin Transl Oncol 2024 Dec;
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-12-23 / Clin Transl Oncol 2024 Dec;2024-12-23 00:00:002024-12-23 00:00:00Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-12-17 / Cancers (Basel) 2024 Dec;16(24)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-12-17 / Cancers (Basel) 2024 Dec;16(24)2024-12-17 00:00:002024-12-17 00:00:00Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-11-04 / Expert Opin Biol Ther 2024 Nov;24(11):1245-1259
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-11-04 / Expert Opin Biol Ther 2024 Nov;24(11):1245-12592024-11-04 00:00:002025-02-25 11:05:42The future of cellular therapy for the treatment of renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-10-09 / Oncoimmunology 2024;13(1):2412876
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-10-09 / Oncoimmunology 2024;13(1):24128762024-10-09 00:00:002024-10-09 00:00:00Trial watch: anticancer vaccination with dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-09-14 / Cureus 2024 Sep;16(9):e69429
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-09-14 / Cureus 2024 Sep;16(9):e694292024-09-14 00:00:002024-09-14 00:00:00Complete Cure of Inoperable Stage IV Locally Advanced Hypopharyngeal Squamous Cell Carcinoma by an Innovative Combination Cancer Immunotherapy Consisting of Radiation, Immune Checkpoint Inhibitors, and Dendritic Cell Vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-09-13 / Oncol Lett 2024 Nov;28(5):550
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-09-13 / Oncol Lett 2024 Nov;28(5):5502024-09-13 00:00:002024-09-13 00:00:00induction of anti‑lung cancer immune response by the A549 lung cancer stem cell lysate‑sensitized dendritic cell vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-09-06 / Front Immunol 2024;15:1376704
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-09-06 / Front Immunol 2024;15:13767042024-09-06 00:00:002025-09-04 16:45:39Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review
